Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Chronic Idiopathic Constipation (CIC) Treatment Market Forecast including Production,
Consumption, Import and Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Chronic Idiopathic Constipation (CIC) Treatment Market – Competitive Analysis
Key players in chronic idiopathic constipation treatment market are Ironwood Pharmaceuticals,
Allergan, Synergy Pharmaceuticals, Inc., Shire plc, and Mallinckrodt plc. The presence of very
few market player provides wide opportunity for new entrant in chronic idiopathic constipation
market. Moreover, in February 2018, Mallinckrodt plc, global specialty pharmaceutical
company, announced acquisition of Sucampo Pharmaceuticals, Inc., a biopharmaceutical
company. The acquisition assets includes its FDA approved blockbuster drug Amitiza
(lubiprostone) for the treatment of chronic idiopathic constipation (CIC) in adults, irritable
bowel syndrome with constipation (IBS-C). The Sucampo Pharmaceuticals, Inc. also partnered
with Par Pharmaceuticals, Inc. and Dr. Reddy’s Laboratories Ltd. As a part of the agreement
both the partners were granted a non-exclusive license to market Par's generic version of
lubiprostone in the U.S. from January, 2021. Such inorganic strategies of market players are
expected to boost growth of the market significantly over the forecast period. In 2012, Ferring
Pharmaceuticals acquired the rights for development and commercialization of Elobixibat, first-
in-class compound for chronic idiopathic constipation from Albireo AB, a Swedish biotechnology
company. Further, in 2013, Ferring Pharmaceuticals, initiated phase III clinical trials of
Elobixibat.
Inquire Here Before Purchase of Research Report @
https://www.coherentmarketinsights.com/insight/talk-to-analyst/1791
Chronic Idiopathic Constipation (CIC) Treatment Market Taxonomy
On the basis of drug, the chronic idiopathic constipation treatment market is segmented into:
• Linaclotide
• Plecanatide
• Lubiprostone